Introduction
Neuroendocrine tumors (NET) are a rare, heterogeneous group of malignancies 1, 2 . Typically, this category of malignancies are difficult to diagnose and treat 3 . While surgery can sometimes provide a curative treatment for patients with localized disease, NETs often present as late stage tumors with advanced metastatic disease 3 , making surgical resection impossible. Traditional chemotherapy and radiation treatment regimens may not be beneficial for patients with disseminated NETs.
A common feature of differentiated NETs is a high level expression of somatostatin receptors on their cell surface. This feature has been exploited by the use of radiolabeled somatostain analogues as a tool for diagnosis and treatment for NETs 4 . Scintigraphy with indium-111 labeled somatostatin analogue pentetreotide is a common method of detection of somatostatin receptor positive NETs. Ga-68 labeled somatostatin analogues have also been used for PET-CT scan in these patients recently 5 .
Indium-111 is a gamma emitter that also emits Auger and conversion electrons during its decay cycle. These electrons emit high energy at close range and are capable of inducing cytotoxic DNA damage 6 . Peptide receptor radionuclide therapy (PRRT) using somatostatin analogues labeled with high activity In-111 pentetreotide has been reported to be a safe and effective therapy for NETs 7, 8 .
The first clinical trial of In-111 pentetreotide for the treatment of NETs was performed by Krenning et al. 7 in Netherlands in 1994. Preliminary data from this study demonstrated the safety of repeated treatments with 90-180 mCi (3.3-6.6 GBq) of In-111 pentetreotide administered every 3 weeks for 10 cycles. In this initial study, response correlated with receptor expression. Subsequent studies conducted by the same group confirmed these preliminary findings 8 . Likewise, additional investigational studies have reported significant responses to high-activity In-111 pentetreotide therapy (180-500 mCi (6.6-18.5 GBq) /treatment) with limited toxicity [7] [8] [9] [10] [11] [12] [13] [14] [15] . These studies vary in patient selection, dosing, total activity administered, and reported outcomes, but all show significant benefits and safety of In-111 pentetreotide therapy.
Generally, studies using higher activity of In-111 (180-500 mCi (6.6-18.5 GBq)) report a greater impact on disease stabilization than those using lower activity while still not reaching the maximum-tolerated dose (MTD). We previously reported the safety and efficacy of high activity In-111 pentetreotide therapy in 32 patients who were treated with one or two cycles of 500 mCi (18.5 GBq) activity. The majority of these patients demonstrated disease stabilization and symptomatic improvement, with minimal hematologic toxicity. No evidence of long-term renal toxicity was reported in patients who were followed for an average of 12 months 16 .
Here, we report on the long-term safety and efficacy of high-activity In-111 pentetreotide in 112 patients who received one, two, three or four cycles of 500 mCi (18. 
Materials and Methods

Patient selection and enrollment
Patients diagnosed with histopathologically confirmed progressive NETs were enrolled in non-randomized trial to evaluate the safety and efficacy of high-dose In-111 pentetreotide therapy in an out-patient setting. This study was performed under approval from the institutional review board at St. Luke's Episcopal hospital, a Baylor College of Medicine affiliated hospital in Texas Medical Center and under an investigational new drug (IND) application from the United States Food and Drug Administration (FDA). All patients gave informed consent prior to treatment.
All patients demonstrated disease progression and had failed routine standard therapy prior to enrollment in the current study. The patients had Karnofsky performance status of higher than 60. The patients had well differentiated neuroendocrine tumors with or without multiple liver metastases. Inclusion criteria required patients to demonstrate histopathological confirmation of NETs and positive somatostatin receptor scintigraphy. Tumor markers and function were included for diagnosis, such as chromogranin A, serotonin, pancreastatin, gastrin, Neurokinin A, pancreatic polypeptide normetanephrine, alkaline phosphatase (ALP), and 24-h urine 5-hydroxyindole acetic acid (5-HIAA). All included patients had a positive OctreoScan with an uptake grading equal to or exceeding 3 in a 4-point graded scale, also known as Krenning score.
Preparation of High dose In-111 pentetreotide
High dose In-111 pentetreotide was prepared as previously described 15 . Indium-111 chloride ( 111 InCl3) was purchased from MDS Nordion (Ottawa, ON, Canada), and purified prior to radiolabeling by IsoTex Diagnostics, Inc. (Friendswood, TX). The synthesis of a therapeutic dose of In-111 pentetreotide was obtained by adding ultra-pure 111 InCl3 (~500 mCi (18.5 GBq)) to 3 standard kits of commercially available Pentetreotide under aseptic conditions. 30µg peptide is used for each therapy.
Treatment Protocol
Patients were injected with In-111 pentetreotide as an intravenous infusion in physiological saline using a specially designed, lead lined IV pole to decrease radiation exposure to the personnel. The infusion duration was approximately 3 hours, and was performed in an outpatient setting. No amino acid infusion was administered before or after the therapy. Patients were evaluated for adverse events immediately following the therapy and hematological, renal and hepatic toxicities using NCI common toxicity criteria on week 4, 5, 6, and 7 after each cycle of treatment, and every three months thereafter. Patients were eligible for 2 nd and 3 rd therapy cycles 9-12 weeks after treatment. The 4 th treatment was given approximately 6 months after the third cycle. These patients were evaluated for a clinical and metabolic response prior to each cycle of therapy by interview, completion of quality of life questionnaire and imaging studies, such as CT scan, MRI, Octreoscan and F-18 FDG PET-CT scan.
Dosimetry and biodistribution of In-111 pentetreotide
In-111 pentetreotide scintigraphy for dosimetry, visualization of tumor spread and assessment of radionuclide uptake intensity was performed. Patients were injected intravenously with 5 to 6 mCi (185-222 MBq) of 111 In-pentetreotide (Mallinckrodt Medical, St. Luis, MO-USA). Static anterior-posterior images were collected, and a single-photon emission computed tomography (SPECT) study was carried out over the regions of tumor using a dual detector gamma scintillation SPECT camera equipped with a medium-energy general purpose collimator (Siemens E-cam). For each patient, whole-body images were performed 10 minutes after injection (before voiding), and at 2, 4, 24, and 48 hours. Regions of interest (ROI) were drawn around the major organs: liver, spleen, kidneys, urinary bladder and whole-body. The data points representing the percentage injected dose (%ID/organ) were then created and fitted to a mono-exponential, bio-exponential, or an uptake/clearance curve. After curve fitting and integration, the cumulative activity and residence time (t) was calculated for each organ. The femur curve was used to estimate the cumulative activity in the bone marrow. The radiation absorbed dose was calculated by entering the corresponding residence time into the OLINDA software program 17 , which computed the radiation-absorbed dose values as mGy/MBq or (rad/mCi) for each of the target organs.
Statistical analysis
Kaplan-Meier survival analysis, Log-rank and Wilcoxon tests were performed using Graph-pad Prism 5 software (Graph Pad Software, Inc. La Jolla, CA). All survival times were calculated from the date of the first treatment.
RESULTS
One hundred and twelve patients (68 male, 44 female) with somatostatin receptor positive NETs underwent treatment with high activity (500 mCi (18. ) ). Patient who received one cycle of therapy had an average dose to kidney of 334 rad (range 134-712 rad). Patients who received two cycles of therapy had a cumulative renal dose of 563 rad (range 63-578 rad) and patients who received three treatments had a cumulative renal dose of 654 rad (range 329-2273 rad) and patients who received the four cycles had cumulative average renal dose of 1132 rad (550-1987 rad). Ninty-six patients (85.7%) had gastroenteropancreatic neuroendocrine tumor (GEP-NET) cancer (67 patients (59.8%) with carcinoid cancer and 29 (25.8%) with pancreatic NET), 5 patients (4.4%) had pulmonary NET, 4 patients (3.6%) had thymic NET, and the rest of 7 patients (6.2%) had other subtypes of neuroendocrine cancer. No significant acute toxicity was observed immediately following treatment and no patients required supportive treatment during therapy. Eleven patients (9.8%) had skin rash after treatment and 12 patients (10.7%) had mild to moderate nausea/vomiting after their treatment.
Patients were evaluated for evidence of toxicity using NCI common toxicity criteria and followed for an average of 25 months (1.2-56 months, median 18.65 months). Of 92 evaluable patients, 7 patients (7.6%) had grade 2 or 3 hematological toxicity, which did not require supportive therapy. Duration of hematological toxicities was 3 weeks (range 1-6 weeks). Grade 2 or 3 liver toxicity was observed in 17 patients (18.4%). Patients with neuroendocrine liver metastases who had abnormal liver enzymes and alkaline phosphatase (ALP) levels prior to therapy did not show any significant worsening as a result of the therapy. In addition, 5 patients (6.1%) had renal toxicity grade one. Of these patients, 1 patient had received 1 cycle of therapy, 2 patients had received 2 therapies and 2 patients had received 3 therapies. No significant renal toxicity was observed and there was no correlation between renal toxicity and cumulative dose to the kidneys.
Radiological response was initially assessed in 80 evaluable patients for an average of 29 months (1.26-60.2 months) following their last therapy. Analysis was using the Response Evaluation Criteria in Solid Tumors criteria (RECIST criteria). A partial radiological response was observed in 6 patients (7.5%). Stable disease was observed in 68 patients (85%). The remaining 6 (7.5%) patients had progressive disease.
Hormonal response was assessed in 36 evaluable patients who received three or four cycles of therapy. A biochemical response (>25% reduction from pretreatment levels in at least one of the markers (Chromogranin A, Serotonin, 5-HIAA)) was observed in 12 patients (33%). 32% of patients had increased levels of all hormonal markers when compared to pre-treatment levels. Statistically, there is no significant difference in tumor marker (Chromogranin A, Serotonin) levels before and after the therapy assays.
Kaplan-Meier survival analysis was conducted on patients who received 2 or more therapies (Fig. 1) . In order to clarify whether there is any correlation between disease burden and survival time, we studied the abdominal CT scan or MRI of 80 evaluable patients who had received at least 2 cycles of therapy and based on the extent of the liver involvement we subcategorized the patients into low bulk, with less than 50% liver involvement, and high bulk, with higher than 50% liver involvement. We realized that average survival time of patients (n= 40) with high liver involvement after two cycles of therapy is 21.96 months. However, average survival rate in patients (n=40) with lower liver burden is 28.3 months (Log-rank test P = 0.0805, 95% CI). Similarly, the survival of patients with less liver involvement who received three or four cycles of therapy is higher, although not statistically significantly, than patients with high liver burden (P = 0.2754 and P = 0.2210, respectively with 95% CI). These findings suggest that among the patients who have received the same number of therapy cycles, patients with lower liver burden live longer than high bulk group, although this difference is not statistically significant. Importantly, patients who received higher number of therapy could live longer.
Of the 42 patients who had pretreatment PET imaging, 31 patients had positive FDG scans (SUV > 2.5) with an average survival time of 18.9 months (range 1.4-45.8 months) and 11 patients had negative FDG scans (SUV ≤ 2.5) with an average survival time of 31.8 months (range 7.4-42.9 months). Survival times for FDG negative patients were significantly longer than those for FDG positive patients (P = 0.001 with 95% confidence).
All patients were asked to complete the functional Living Index questionnaire to assess and compare the quality of life before and after their last cycle of therapy. In patients who received 2 or more cycles of In-111 pentetreotide therapy data showed improvement in social, family, emotional and functional aspects of patient life, particularly following 3 cycles of In-111 PRRT therapy.
DISCUSSION
Neuroendocrine tumors are a rare, heterogeneous group of malignancies and the incidence of this cancer has significantly increased over the past three decades 1, 2 . Typically, these cancers are difficult to diagnose and treat 3 . While surgery can sometimes provide a curative treatment for patients with localized disease, NETs often present as late stage tumors with advanced metastatic disease 3 .
A common feature of differentiated NETs is a high level expression of somatostatin receptors on their cell surface. This feature has been exploited by the use of radio-labeled somatostatin analogues as a tool for diagnosis and treatment for NETS 4 .
Peptide receptor radionuclide therapy (PRRT) using different radiolabeled somatostatin analogues such as In-111 DTPA-Octreotide, Lu-177 DOTATATE and Y-90 DOTATOC have been used for the treatment of disseminated well differentiated neuroendocrine cancers.
The first clinical trial of In-111 pentetreotide for the treatment of NETs was performed by Krenning et al. 7 in Netherlands in 1994. Preliminary data from this study demonstrated the safety of repeated treatments with 90-180 mCi (3.3-6.6 GBq) of In-111 pentetreotide administered every 3 weeks for 10 cycles. In this initial study, response correlated with receptor expression. Subsequent studies conducted by the same group confirmed these preliminary findings 8 . Likewise, additional investigational studies have reported significant responses to high-activity In-111 pentetreotide therapy (180-500 mCi (6.6-18.5 GBq)/treatment) with limited toxicity [7] [8] [9] [10] [11] [12] [13] [14] [15] . These studies vary in patient selection, dosing, total activity administered, and reported outcomes, but all show sig-nificant benefits and safety of In-111 pentetreotide therapy.
Previously, in a study performed on 26 patients, Anthony et al 18 reported SD in 81% of patients along with CR + PR equals to 8%, and 12% of the patients showed progression. In their study, 62% of the patients experienced symptomatic relief or improvement and median survival was 18 months. Similarly, our prior study 16 performed on 18 patients showed clinical response in 84% of the patients, CR + PR equals to 11% and median survival rate as high as 13.3 months. The results of our current study are consistent with these findings.
Another radiolabeled somatostatin analog that is used for PRRT is Y-90 DOTATOC. Various phase 1 and phase 2 PRRT trials have been performed with this compound 17 . Waldherr et al 20, 21, 22 performed several studies using Y-90 DOTATOC in populations of patients with neuroendocrine cancer. Data from Y-90 DOTATOC studies showed CR + PR rates as high as 24% 20, 21 and 33% 22 . However, similar to the data from Anthony et al. 18 , progressive disease was seen in 11% 20, 21 and 9% 22 of patients.
In another study, Kwekkeboom and his colleagues 23 administered Lu-177 DOTATATE for treatment of 310 patients with neuroendocrine cancer. The data showed CR + PR in 29% of patients. By including patients with minor response (MR), this number increased to 45%. Stable disease was reported in 35% of cases.
It is generally accepted that stable disease is the predominant response seen after In-111 pentetreotide therapy 16, 18 ; although stable disease is still the common outcome after Y-90 20, 21, 22 or Lu-177 23, 28, 29 therapies, however, partial response rate is generally higher after Y-90 or Lu-177 radionuclide therapies. Nonetheless, in order to study the toxicity profile of patients and to compare the efficacy of each therapy, a randomized clinical trial is needed.
Lu-177 DOTATATE therapies using 4 cycles of 200 mCi (7.4 GBq) Lu-177 DOTATATE and Y-90 DOTATOC using maximum 6 GBq (160 mCi )/m 28 or 7.4 GBq (200 mCi )/m 29 in four cycles produce more cases of PR and CR with requirement of protection of the kidneys using amino acid infusion. Hematological and nephrotoxicity appears to be more common following these therapies while it is rare with In-111 Octreotide therapy.
Recently attempts to improve response to PRRT have included tandem treatments with different radiolabeled analogues. A response to Lu-177 DOTATATE therapy was observed in patients who had previously undergone previous treatment with Y-90 DOTATOC. No additional hematological or renal toxicity was observed. Clinical response to Y-90 DOTATOC was predictive of response to Lu-177 DOTATATE 24 . Retrospective analysis of patients who received up to three cycles of Lu-177 Octreotate following high dose In-111 Pentetreotide therapy showed no significant increase in toxicity 25 , although the effect of tandem therapies on long-term progression free survival remains unclear. As we reported before 16 , due to different peneteration range in tissue, In-111, Y-90 and Lu-177 behave differently once introduced into the tissues. In-111 emits Auger electrons and γ-rays. The Auger electrons have a maximum penetration range in tissue of 10 μm. In comparison, Y-90 is a pure β-emitter with a maximum penetration range in tissue of 12 mm and 177Lu is a β-emitter with a maximum particle range in tissue of 2 mm. Lu-177 also emits γ-rays, which allows imaging and dosimetry. These differences in particle range may have therapeutic advantages as patients usually have tumors of various sizes.
Additionally, radiosensitizers have been used to improve response to PRRT. The addition of Capecitabine or 5-FU to PRRT has shown no increase in early or late toxicity, and has been shown to improve tumor control and disease stabilization 26 . In terms of the disease burden, there was no significant difference between the number of patients with high bulk liver involvement (50%) and low bulk patients (50%).
It is noteworthy that since In-111 is a gamma emitter agent, in order to perform the dosimetry studies and also for imaging purposes, unlike the Y-90-a pure beta emitter-, we do not need a surrogating agent; hence, therapy, dosimetry and imaging is done using the same agent. This is one of the advantages of the in-111 therapy which provides an ease in performing the peptide receptor radionuclide therapy.
Quality of life (QOL) is an important issue in cancer therapy. Previously, Khan et al. 27 investigated QOL and symptoms after Lu-177 octreotate therapy in patients with inoperable or metastasized gastroenteropancreatic or bronchial neuroendocrine tumors (NETs). The study looked at differences of at least 10 points in global health status (GHS)/QOL scores, symptom scores, and Karnofsky performance scores (KPS) before and after therapy. They realized that regardless of the treatment outcome, patients' quality of life including insomnia, appetite loss, and diarrhea improved significantly. Similarly, Teunissen et al. 28 evaluated the results of self-assessment questionnaire filled by patients after they received Lu-177 DOTATATE therapy. Kwekkeboom et al 29, 30 showed that other radionuclide materials including Indium-111 and Y-90 are able to improve the QOL of pa-tients in a similar manner. Our study revealed significant improvement in social, family, emotional and functional aspects of patient life and supports previous studies. 
CONCLUSION
Our findings demonstrate that high-activity In-111 Pentetreotide therapy is a safe, effective therapy for patients with disseminated neuroendocrine tumors. Our results suggest that the long-term toxicity profile of this agent is excellent, with no major hematological, renal or liver toxicity observed. The absence of renal toxicity at cumulative dose up to 2000 mCi (74 GBq) suggests that maximal tolerated renal doses have not been reached.
While the observed radiological responses were mostly disease stabilization by the RECIST criteria rather than marked disease regression, this treatment regimen has a clear survival benefit as compared to historical data with limited toxicity. In our study, survival time was increased in patients who received three cycles of therapy compared to those who had two cycles of therapy. The greatest survival times following therapy were observed for patients with islet cell tumors. Tumors originating in the pancreas have been reported to have very high expression of somatostatin receptors and we speculate that this may increase the cellular uptake of the radiotracer and consequently improve the effectiveness of the radiolabeled peptide. Survival times were significantly lower in patients who had multiple sites of metastasis compared to those who had metastasis at only one site. This is most likely due to higher disease burden at the start of treatment and suggests that response rates may be greater for patients with mid-stage disease rather than those with very late stage disease.
There is an increase, although not statistically significant, in survival time in patients with less than 50% of their liver involved compared to patients with more than half hepatic involvement. Pretreatment FDG status may be a predictor of survival following In-111 pentetreotide therapy.
Hormonal evaluation was performed in patients who had three or more cycles of therapy, but due to a small sample size no statistically significant difference was seen in tumor marker levels before and after the therapy session.
The non-randomized nature of our study is the primary limitation and a randomized clinical trial will be required to determine if multiple cycles of therapy can increase survival times. Moreover, due to the small population, survival advantages for NETs other than carcinoid and islet cell tumors could not be determined.
